Mereo BioPharma Group plc (MREO)
| Market Cap | 389.36M |
| Revenue (ttm) | 10.00M |
| Net Income (ttm) | -29.47M |
| Shares Out | 140.06M |
| EPS (ttm) | -0.25 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 572,889 |
| Open | 2.760 |
| Previous Close | 2.780 |
| Day's Range | 2.760 - 2.885 |
| 52-Week Range | 0.920 - 4.360 |
| Beta | 0.78 |
| Analysts | Strong Buy |
| Price Target | 6.50 (+133.81%) |
| Earnings Date | Mar 27, 2024 |
About MREO
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 ... [Read more]
Analyst Forecast
According to 2 analysts, the average rating for MREO stock is "Strong Buy." The 12-month stock price forecast is $6.5, which is an increase of 133.81% from the latest price.
News
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced tha...
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
LONDON, March 05, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced tha...
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta (OI) conducted by partner Ultragenyx expected to complete enrollment around the end of 1Q...
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an up...
Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced tha...
Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update
LONDON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its...
Mereo BioPharma to Present at the Jefferies Healthcare Conference
LONDON, May 31, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that ...
Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma's Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference
LONDON, May 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases today announced that ...
Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
LONDON, May 08, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that ...
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
LONDON, May 05, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that ...
Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights
LONDON, March 28, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its...
Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease
Clear path forward with proposed single Phase 3 study evaluating alvelestat at the 240 mg dose level versus placebo at 12-18 months for potential full approval in both the U.S. and EU
Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference
LONDON, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today a...
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency
LONDON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today ...
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
Mereo to Appoint Four New Directors to its Board of Directors
Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022
LONDON, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today ...
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
Reiterates Quality and Composition of Mereo's Significantly Refreshed Board, which has the Right Skills and Experience to Guide Mereo's Strategy and Maximize Shareholder Value
Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan
NEW YORK--(BUSINESS WIRE)--Rubric Capital Management LP (“Rubric”), an investment advisor whose funds and accounts collectively own approximately 14% of the outstanding equity of Mereo BioPharma Group...
Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value
Targets 40% Reduction in Headcount and Significant Expense Reductions as Company Continues to Guide Lead Programs Through Upcoming Value Creating Milestones
Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease
Designation Validates Alvelestat's Potential to Address a Serious Unmet Need
Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders
Rubric has Rejected Mereo's Reasonable Settlement Proposal and has Escalated its Costly, Distracting Proxy Campaign to Now Seek Control of Mereo's Board
Rubric Capital Management Increases Slate of Proposed Mereo BioPharma Director Nominees to Five
NEW YORK--(BUSINESS WIRE)--Rubric Capital Management LP (“Rubric”), an investment advisor whose funds and accounts collectively own approximately 14% of the outstanding equity of Mereo BioPharma Group...
Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the Board
Rubric Summarily Rejected the Proposal and Refused to Provide a Counteroffer
Rubric Capital Management Issues Open Letter to Mereo BioPharma Shareholders
NEW YORK--(BUSINESS WIRE)--Rubric Capital Management LP (“Rubric”), an investment advisor whose funds and accounts collectively own approximately 14% of the outstanding equity of Mereo BioPharma Group...